title: Fibrosing cholestatic hepatitis after living related-donor renal transplantation.
abstract: A 43-year-old man underwent living related-donor renal transplantation because of chronic renal failure in 1991. During the transplant period, both donor and recipient were seronegative for hepatitis B surface antigen (HBsAg). The donor was seropositive for antibody to hepatitis B surface antigen (anti-HBs) due to hepatitis B virus (HBV) vaccination. After transplantation, FK506 and methylprednisolone had been administered to the patient as immunosuppressants. In 1993, HBsAg appeared in his serum. His alanine aminotransferase level elevated gradually during 1995 and then in 1996, general fatigue, ascites and jaundice developed. At this time his serum was positive for hepatitis B e antibody, contained more than 100000 Meq/mL HBV-DNA and 100% precore mutant. Despite subsequent intensive therapy, liver dysfunction progressed and this patient died of hepatic failure 2 months following admission. At autopsy, the liver exhibited cholestasis, fibrosis extending from the portal tracts, mild inflammation and hepatocytes with a ground-glass appearance. In addition, HBsAg and hepatitis B core antigens had accumulated in the hepatocytes. Consequently, the final diagnosis was fibrosing cholestatic hepatitis (FCH) due to precore mutant HBV infection contracted after renal transplantation. It is unclear when and where the recipient liver became HBV infected. Nevertheless, after renal transplantation, while receiving immunosuppressive drugs, HBV appeared to have the potential to cause hepatic failure and FCH may have been a fatal complication for the recipient.
authors.affiliation: Department of Internal Medicine III, Niigata University School of Medicine, Niigata City, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Waguri
authors.forename: T
authors.initials: T
authors.lastname: Ichida
authors.forename: R
authors.initials: R
authors.lastname: Fujimaki
authors.forename: T
authors.initials: T
authors.lastname: Ishikawa
authors.forename: M
authors.initials: M
authors.lastname: Nomoto
authors.forename: H
authors.initials: H
authors.lastname: Asakura
authors.forename: T
authors.initials: T
authors.lastname: Nakamaru
authors.forename: A
authors.initials: A
authors.lastname: Saitoh
authors.forename: M
authors.initials: M
authors.lastname: Arakawa
authors.forename: K
authors.initials: K
authors.lastname: Saitoh
authors.forename: K
authors.initials: K
authors.lastname: Takahashi
mesh_terms: D000328:Adult; D002779:Cholestasis / Q000276:immunology / Q000473:pathology*; D017809:Fatal Outcome; D005355:Fibrosis; D006509:Hepatitis B / Q000276:immunology / Q000473:pathology*; D006511:Hepatitis B Antigens / Q000032:analysis; D006801:Humans; D007124:Immunoenzyme Techniques; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation / Q000473:pathology*; D008297:Male; D011183:Postoperative Complications / Q000473:pathology*
chemical_list: D006511:Hepatitis B Antigens; D007166:Immunosuppressive Agents